Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. Issue 11 (7th June 2017)

• Record Type: Journal Article
• Authors: Hanefeld, Markolf; Arteaga, Juan M.; Leiter, Lawrence A.; Marchesini, Giulio; Nikonova, Elena; Shestakova, Marina; Stager, William; Gómez‐Huelgas, Ricardo
• Is Part Of: Diabetes, obesity & metabolism. Volume 19:Issue 11(2017)
• Page Start: 1594
• Page End: 1601
• Publication Date: 2017-06-07
• Subjects: GLP‐1 -- incretin therapy -- meta‐analysis -- type 2 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12986
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : Aims: This post hoc assessment evaluated the efficacy and safety of once‐daily, prandial glucagon‐like peptide‐1 receptor agonist lixisenatide in patients with type 2 diabetes (T2D) and normal renal function (estimated glomerular filtration rate ≥90 mL/min), or mild (60‐89 mL/min) or moderate (30‐59 mL/min) renal impairment. Methods: Patients from 9 lixisenatide trials in the GetGoal clinical trial programme were categorized by baseline creatinine clearance: normal renal function (lixisenatide n = 2094, placebo n = 1150); renal impairment (mild: lixisenatide n = 637, placebo n = 414; moderate: lixisenatide n = 122, placebo n = 68). Meta‐analyses of placebo‐adjusted mean differences between baseline renal categories were performed for efficacy and safety outcomes. Results: HbA1c, 2‐hour postprandial plasma glucose and fasting plasma glucose were comparably reduced in lixisenatide‐treated patients with normal renal function, and mild and moderate renal impairment. The most common adverse events (AEs) in all renal function categories were gastrointestinal (GI), predominantly nausea and vomiting. A 14% higher incidence of GI AEs and a 10% higher incidence of nausea and vomiting were seen with mild impairment vs normal function ( P = .003 for both), but no significant differences were observed between the mild and moderate impairment categories ( P = .99 and P = .57, respectively), or between the moderate impairment and normal categories ( P = .16 and P = .65, respectively). Additionally, the incidence of hypoglycaemia was similar in all categories. Conclusions: This study demonstrates that baseline renal status does not affect efficacy outcomes in lixisenatide‐ vs placebo‐treated patients, and that no lixisenatide dose adjustment is required for patients with T2D with mild or moderate renal impairment.